Cargando…

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access through a Named Patient Program. A multicentric observational retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Argnani, Lisa, Broccoli, Alessandro, Pellegrini, Cinzia, Fabbri, Alberto, Puccini, Benedetta, Bruna, Riccardo, Tisi, Maria Chiara, Masia, Francesco, Flenghi, Leonardo, Nizzoli, Maria Elena, Musso, Maurizio, Salerno, Marilena, Scalzulli, Potito Rosario, Dessi’, Daniela, Ferrarini, Isacco, Pennese, Elsa, Lucchini, Elisa, Rossi, Francesca Gaia, Minoia, Carla, Gherlinzoni, Filippo, Musto, Pellegrino, Patti, Caterina, Stefoni, Vittorio, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663137/
https://www.ncbi.nlm.nih.gov/pubmed/36398133
http://dx.doi.org/10.1097/HS9.0000000000000798
_version_ 1784830804428324864
author Argnani, Lisa
Broccoli, Alessandro
Pellegrini, Cinzia
Fabbri, Alberto
Puccini, Benedetta
Bruna, Riccardo
Tisi, Maria Chiara
Masia, Francesco
Flenghi, Leonardo
Nizzoli, Maria Elena
Musso, Maurizio
Salerno, Marilena
Scalzulli, Potito Rosario
Dessi’, Daniela
Ferrarini, Isacco
Pennese, Elsa
Lucchini, Elisa
Rossi, Francesca Gaia
Minoia, Carla
Gherlinzoni, Filippo
Musto, Pellegrino
Patti, Caterina
Stefoni, Vittorio
Zinzani, Pier Luigi
author_facet Argnani, Lisa
Broccoli, Alessandro
Pellegrini, Cinzia
Fabbri, Alberto
Puccini, Benedetta
Bruna, Riccardo
Tisi, Maria Chiara
Masia, Francesco
Flenghi, Leonardo
Nizzoli, Maria Elena
Musso, Maurizio
Salerno, Marilena
Scalzulli, Potito Rosario
Dessi’, Daniela
Ferrarini, Isacco
Pennese, Elsa
Lucchini, Elisa
Rossi, Francesca Gaia
Minoia, Carla
Gherlinzoni, Filippo
Musto, Pellegrino
Patti, Caterina
Stefoni, Vittorio
Zinzani, Pier Luigi
author_sort Argnani, Lisa
collection PubMed
description After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access through a Named Patient Program. A multicentric observational retrospective study was conducted focusing on the effectiveness and safety of PolaBR in everyday clinical practice. Fifty-five patients were enrolled. There were 26 females (47.3%), 32 patients were primary refractory and 45 (81.8%) resulted refractory to their last therapy. The decision to add or not bendamustine was at physician’s discretion. Thirty-six patients underwent PolaBR, and 19 PolaR. The 2 groups did not differ in most of baseline characteristics. The final overall response rate was 32.7% (18.2% complete response rate), with a best response rate of 49.1%. Median disease-free survival was reached at 12 months, median progression-free survival at 4.9 months and median overall survival at 9 months, respectively. Overall, 88 adverse events (AEs) were registered during treatment in 31 patients, 22 of grade ≥3. Eight cases of neuropathy occurred, all of grades 1–2 and all related to polatuzumab. The two groups of treatment did not differ for effectiveness endpoints but presented statistically significant difference in AEs occurrence, especially in hematological AEs, in AEs of grade equal or greater than 3 and in incidence of neuropathy. Our data add useful information on the effectiveness of Pola(B)R in the setting of heavily pretreated DLBCL and may also suggest a better tolerability in absence of bendamustine without compromise of efficacy.
format Online
Article
Text
id pubmed-9663137
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96631372022-11-16 Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy Argnani, Lisa Broccoli, Alessandro Pellegrini, Cinzia Fabbri, Alberto Puccini, Benedetta Bruna, Riccardo Tisi, Maria Chiara Masia, Francesco Flenghi, Leonardo Nizzoli, Maria Elena Musso, Maurizio Salerno, Marilena Scalzulli, Potito Rosario Dessi’, Daniela Ferrarini, Isacco Pennese, Elsa Lucchini, Elisa Rossi, Francesca Gaia Minoia, Carla Gherlinzoni, Filippo Musto, Pellegrino Patti, Caterina Stefoni, Vittorio Zinzani, Pier Luigi Hemasphere Article After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access through a Named Patient Program. A multicentric observational retrospective study was conducted focusing on the effectiveness and safety of PolaBR in everyday clinical practice. Fifty-five patients were enrolled. There were 26 females (47.3%), 32 patients were primary refractory and 45 (81.8%) resulted refractory to their last therapy. The decision to add or not bendamustine was at physician’s discretion. Thirty-six patients underwent PolaBR, and 19 PolaR. The 2 groups did not differ in most of baseline characteristics. The final overall response rate was 32.7% (18.2% complete response rate), with a best response rate of 49.1%. Median disease-free survival was reached at 12 months, median progression-free survival at 4.9 months and median overall survival at 9 months, respectively. Overall, 88 adverse events (AEs) were registered during treatment in 31 patients, 22 of grade ≥3. Eight cases of neuropathy occurred, all of grades 1–2 and all related to polatuzumab. The two groups of treatment did not differ for effectiveness endpoints but presented statistically significant difference in AEs occurrence, especially in hematological AEs, in AEs of grade equal or greater than 3 and in incidence of neuropathy. Our data add useful information on the effectiveness of Pola(B)R in the setting of heavily pretreated DLBCL and may also suggest a better tolerability in absence of bendamustine without compromise of efficacy. Lippincott Williams & Wilkins 2022-11-11 /pmc/articles/PMC9663137/ /pubmed/36398133 http://dx.doi.org/10.1097/HS9.0000000000000798 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Argnani, Lisa
Broccoli, Alessandro
Pellegrini, Cinzia
Fabbri, Alberto
Puccini, Benedetta
Bruna, Riccardo
Tisi, Maria Chiara
Masia, Francesco
Flenghi, Leonardo
Nizzoli, Maria Elena
Musso, Maurizio
Salerno, Marilena
Scalzulli, Potito Rosario
Dessi’, Daniela
Ferrarini, Isacco
Pennese, Elsa
Lucchini, Elisa
Rossi, Francesca Gaia
Minoia, Carla
Gherlinzoni, Filippo
Musto, Pellegrino
Patti, Caterina
Stefoni, Vittorio
Zinzani, Pier Luigi
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
title Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
title_full Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
title_fullStr Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
title_full_unstemmed Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
title_short Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
title_sort real-world outcomes of relapsed/refractory diffuse large b-cell lymphoma treated with polatuzumab vedotin-based therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663137/
https://www.ncbi.nlm.nih.gov/pubmed/36398133
http://dx.doi.org/10.1097/HS9.0000000000000798
work_keys_str_mv AT argnanilisa realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT broccolialessandro realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT pellegrinicinzia realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT fabbrialberto realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT puccinibenedetta realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT brunariccardo realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT tisimariachiara realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT masiafrancesco realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT flenghileonardo realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT nizzolimariaelena realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT mussomaurizio realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT salernomarilena realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT scalzullipotitorosario realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT dessidaniela realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT ferrariniisacco realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT penneseelsa realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT lucchinielisa realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT rossifrancescagaia realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT minoiacarla realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT gherlinzonifilippo realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT mustopellegrino realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT patticaterina realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT stefonivittorio realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy
AT zinzanipierluigi realworldoutcomesofrelapsedrefractorydiffuselargebcelllymphomatreatedwithpolatuzumabvedotinbasedtherapy